SCHEMBL6790494

SCHEMBL6790494

CC(=O)Oc1ccc(-c2ccc(C=O)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.59
KMT2A Q03164 5/20 0.56
MAPT P10636 5/20 0.56
LMNA P02545 3/20 0.56
KDM4E B2RXH2 1/20 0.56
MEN1 O00255 1/20 0.56
TTR P02766 1/20 0.56
TP53 P04637 1/20 0.56
CYP3A4 P08684 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
ALDH1A1 P00352 2/20 0.50
GAA P10253 2/20 0.50
CYP2A6 P11509 1/20 0.50
DRD1 P21728 1/20 0.50
POLB P06746 2/20 0.48
PKM P14618 1/20 0.48
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL203500 0.94 KMT2A (0.61) HSD17B10KMT2AMAPTLMNAKDM4E
Benzene SCHEMBL3155393 0.90 KMT2A (0.59) HSD17B10KMT2AMAPTLMNAKDM4E
4-Hydroxybenzaldehyde SCHEMBL9418057 0.87 ALDH5A1 (0.59) HSD17B10KMT2AMAPTLMNAKDM4E
SCHEMBL7013877 0.87 ELANE (0.65) HSD17B10KMT2AMAPTLMNAKDM4E
SCHEMBL329365 0.85 HSD17B10 (0.76) HSD17B10KMT2AMAPTLMNAKDM4E
SCHEMBL9158246 0.85 HSD17B10 (0.76) HSD17B10KMT2AMAPTLMNAKDM4E
SCHEMBL8009088 0.84 ALDH1A1 (0.58) HSD17B10KMT2AMAPTLMNAKDM4E
Water SCHEMBL9344643 0.83 HSD17B10 (0.73) HSD17B10KMT2AMAPTLMNAKDM4E
SCHEMBL6791725 0.83 DRD1 (0.61) KMT2AMAPTLMNAKDM4EMEN1
SCHEMBL10517767 0.83 LMNA (0.61) HSD17B10KMT2AMAPTLMNAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4670581-A Biphenyl compounds and process for producing the same SUGAI CHEMICAL INDUSTRY CO., LTD. (JP) 1987-06-02 US claimed
US-20040147573-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-07-29 US disclosed
US-20040110809-A1 Metalloproteinase inhibitors ASTRAZENECA AB (SE) 2004-06-10 US disclosed
EP-1370536-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
EP-1370538-A1 METALLOPROTEINASE INHIBITORS AstraZeneca AB (SE) 2003-12-17 EP disclosed
WO-2002074752-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed
WO-2002074750-A1 METALLOPROTEINASE INHIBITORS ASTRAZENECA AB (SE) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110809-A1 Metalloproteinase inhibitors MMP9, MMP2, MMP3 HSD17B10 456/4885KMT2A 2773/4885MAPT 4179/4885
US-20040147573-A1 Metalloproteinase inhibitors MMP12, MMP7, MMP10 HSD17B10 174/4885KMT2A 2278/4885MAPT 4451/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.